-
Battling Norrie survives match point to oust de Minaur at Montreal
-
Venezuela's political transition talks launch in Caracas
-
Venezuela's political transition talks start: AFP
-
2 killed, 13 wounded in bus blast near Syrian capital: state media
-
Real Madrid extend Vinicius deal, sign Diomande in title bid boost
-
All Blacks skipper Taylor cautiously recovering from calf strain
-
PSG sign France midfielder Akliouche from Monaco
-
UN chief denounces Russia, Ukraine for civilian deaths
-
CONMEBOL 'expresses concern regarding repeated unilateral actions' by FIFA
-
UEFA turn up the pressure on Infantino and repeat boycott threat
-
Warren coy over whether Fury-Joshua will be in UK or US
-
Rodri approves Barcelona transfer talks with Man City: Barca source to AFP
-
Taiwan blocks key bridge in drill for potential Chinese invasion
-
Venezuela unable to tally missing from cataclysmic quakes
-
Migrant children risk abuse on streets of Ceuta, aid groups warn
-
Le Court sprints to stage six Tour de France Femmes win
-
Oil price shoots up as stocks tread water
-
Doping body says Parker's positive cocaine test caused by nutritionist
-
British Grand Prix stays on MotoGP calendar until 2028
-
UEFA says boycott of World Cups stands despite FIFA backdown on private investment
-
Britain's EasyJet flies into US hands as takeover confirmed
-
Rheinmetall sales keep surging despite cancelled naval frigate project
-
Real Madrid sign Ivory Coast winger Yan Diomande
-
Pogacar teammate Del Toro gets new UAE deal after Tour podium
-
How online disinformation fuelled Ceuta migrant surge
-
Stocks tread water with earnings, tech in focus
-
Forex Expo Dubai Announces Opportunity to Win Up to 150 Grams of Gold This September 2026
-
Inevitable AI Group Raises $6M From Aleph to Launch AI-Native SaaS Companies
-
Suspected Ebola death on boat heading for DR Congo capital
-
Forlan named new Uruguay head coach
-
England selector North not 'hung up' on Stokes absence
-
UEFA chief Ceferin: 'Underdog' leader taking fight to FIFA's Infantino
-
UK Anti-Doping confirm former world champ Parker's ban lifted
-
Salah completes move to Turkey's Trabzonspor
-
French winemakers dread 'smoky taste' after wildfires
-
UK clears Paramount's takeover of Warner Bros
-
Stocks diverge with earnings, tech in focus
-
North Korea fires ballistic missile: South Korea military
-
England recall batsman Lawrence for Pakistan series
-
'Don't have to hide': Thai IDs, legal work give hope to Myanmar refugees
-
Siemens shares plunge on disappointing guidance raise
-
Stocks mixed with tech firms back under pressure
-
New Australia coach Kiss gives Japan starts to Ross, Amatosero
-
How Blundell's old school tactic ended England's 'Bazball' era
-
'Stretch our money': Romanians face highest EU inflation
-
Israel reports troop deaths as Lebanon talks underway in Rome
-
Iran says close to Hormuz plan with Oman, but reopening depends on US
-
Seeds Rybakina, Pegula, Gauff reach third round at WTA Toronto
-
Messi scores twice to set Leagues Cup record in Miami victory
-
Police raid South Korea FA in probe into World Cup coach appointment
Drew Weissman, Nobel-winning mRNA pioneer
Drew Weissman's decades of research into mRNA technology paved the way for Covid-19 vaccines, finally earning a Nobel prize for the physician-scientist.
The 64-year-old University of Pennsylvania immunologist, who won the Nobel Medicine Prize along with long-time collaborator Katalin Kariko on Monday, is far from done.
His next quests include, among others, developing a vaccine against all future coronaviruses.
"There have been three (coronavirus) pandemics or epidemics in the past 20 years," Weissman told AFP recently, referring to the original SARS virus, MERS and Covid-19.
"You have to assume there's going to be more, and our idea was that we could wait for the next coronavirus epidemic or pandemic, and then spend a year and a half making a vaccine. Or we could make one now."
- Twin breakthroughs-
The world is now aware of the elegance of the mRNA (messenger ribonucleic acid) vaccines, that deliver genetic instructions to cells telling them to recreate the spike protein of the coronavirus, in order to trigger effective antibodies when they encounter the real thing.
But back when Weissman teamed up with Kariko in the 1990s, the research was considered a scientific dead-end, and working with DNA was considered a more promising avenue.
"We started working together in 1998, and that was without much funding and without much in the way of publications," he said.
In 2005, the pair found a way to alter synthetic RNA to stop it from causing a massive inflammatory response found in animal experiments.
"Just before our paper was published, I said 'Our phones are going to ring off the hook,'" he recalls.
"We sat there staring at our phones for five years, and they never rang!"
With a second big breakthrough in 2015, they found a new way to deliver the particles safely and effectively to their target cells, using a fatty coating called "lipid nanoparticles."
Both developments are part of the Pfizer and Moderna Covid-19 vaccines today.
- Helping people -
Weissman grew up in Lexington, Massachusetts.
His father and mother, both since retired, were an engineer and dental hygienist, respectively.
"When I was five years old, I was diagnosed as a type-one diabetic, and back then it was testing urine and taking insulin shots a few times a day," he recalled, and this motivated him to pursue science.
He was educated at Brandeis University and completed an MD-Phd program in immunology at Boston University.
As a young fellow at the National Institutes of Health, he worked for several years in Anthony Fauci's lab on HIV research, before finally arriving at his long-time home Penn.
Weissman was a practicing doctor until a few years ago, and says it brings him great joy that his invention has helped save millions of lives.
"I'm a clinician scientist, my dream since starting college and medical school was to make something that helps people. I think I can say that I've done that. So I am incredibly happy," he said.
Beyond vaccines, mRNA technology is also being heralded for its potential across medicine.
Weissman's team is working on using RNA to develop a single-injection gene therapy to overcome the defect that causes sickle cell anemia, a genetic blood disease that 200,000 babies are born with in Africa every year.
Significant technical challenges remain to ensure the treatment is able to correctly edit genes and is safe, but the researchers are hopeful.
Bone marrow transplant, an expensive treatment with serious risks, is currently the only cure.
C.Amaral--PC